Crohn's Disease Global Pipeline Highlights 2018 ResearchAndMarkets.com
ResearchAndMarkets.comLaura Wood Senior Managerpressresearchandmarkets.comFor E.S.T Office Hours Call 19173000470For U.S.CAN Toll Free Call 18005268630For GMT Office Hours Call 35314168900Related...
View ArticleCrohns Disease Global Pipeline Highlights 2018 ResearchAndMarkets.com
DUBLIN&8211;BUSINESS WIRE&8211;The &8220;Crohn&8217;s Disease Pipeline Highlights &8211; 2018&8221; report has been added to ResearchAndMarkets.com&8217;s offering....
View ArticleA Common Antiinflammatory Therapy May Help Reduce the Risk of Developing...
Study shows potential link between Parkinsons disease and inflammatory bowel disease suggests antiTNF therapy may reduce the risk of developing Parkinsons diseaseNEW YORK PRWEB April 23 2018 A recent...
View ArticleNew Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing...
Reductions in annualized relapse rates shown in pivotal trials with ozanimod were consistent in subgroups including baseline disability gadoliniumenhanced lesion status and prior exposure to...
View ArticleOral Biologics Delivery Could Be The Key For Biosimilars
NewsDoctors believe moving Rheumatoid Arthritis and Crohn's Disease patients from AbbVie's injectable Humira adalimumab to an oral adalimumab would improve patient compliance.
View ArticleConnect Biopharmaceuticals Advances CBP201 a Novel Monoclonal Antibody...
TAICANG China April 24 2018 PRNewswire Connect Biopharmaceuticals Ltd. today announced that it has submitted an application in Australia to begin a phase 1 clinical trial to evaluate CBP201 the...
View ArticleTakeda Announces Voluntary and Conditional Public Takeover Bid for...
Prospectus and response memorandum approved by the FSMA on April 24 2018 and to be published on April 27 2018 Initial acceptance period will commence on April 30 2018 and expire on May 31 2018 subject...
View ArticleHealth Tip Manage Symptoms of Crohn's Disease
Crohn's disease is a chronic condition that causes inflammationand irritation of the digestive tract.It affects more than 500000 people in the United States the National Institute of Diabetes and...
View ArticleBoehringer Ingelheim R&D Pushes to Transcend Disease Boundaries
Promising firstinclass and potential medical breakthrough pipeline projects presented at R&D Press Conference 80 clinical and preclinical projects of which 65 have firstinclass and breakthrough...
View ArticleObesity linked to biologics failure in UC
Patients with ulcerative colitis who have a higher BMI are at an increased risk for failing biologic therapy regardless of the dosing regimen according to new research published in Alimentary...
View ArticleZealand announces successful EndofPhase 2 meeting with FDA on glepaglutide...
Company announcement No. 122018 Zealand announces successful EndofPhase 2 meeting with FDA on glepaglutide for short bowel syndrome Glepaglutide is in development as a new treatment option for patients...
View ArticleTillotts Pharma AG Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryTillotts Pharma AG Tillotts a subsidiary of Zeria Pharmaceutical Co Ltd is a healthcare solution provider that develops licenses and markets pharmaceutical products medical devices and...
View ArticleTreating JC Polyomavirus Infection and Associated Leukoencephalopathy
Progressive Multifocal Leukencephalopathy PML is a rare but lethal brain disease caused by JC polyomavirus. PML is a wellknown sideeffect of immunosuppressive drugs and currently the only effective...
View ArticleMorphoSys Announces Approval of TremfyaR Guselkumab in South Korea news with...
DGAPNews MorphoSys AG Key words Regulatory Approval26.04.2018 2200 The issuer is solely responsible for the content of this announcement.PlaneggMunich Germany April 26 2018MorphoSys Announces Approval...
View ArticleuBiome Sponsors Annual Fundraising Walk SF Take Steps to Support the Crohns...
On May 5th uBiome the leader in microbial genomics will be sponsoring SF Take Steps hosted by the Northern California Chapter of the Crohns and Colitis Foundation for the second consecutive year.SAN...
View ArticleSmall biotechs dominating in microbiometargeted therapies
With smaller biotech companies dominating the pipeline for microbiometargeted therapeutics large pharma firms such as Johnson & Johnson J&J are eager to collaborate with biotech...
View ArticleTiGenix Publication of prospectus and response memorandum for Takeda takeover...
PRESS RELEASE Publication of prospectus and response memorandum for Takeda takeover bid commencing on April 30 2018 Leuven BELGIUM April 27 2018 0700h CEST TiGenix NV Euronext Brussels and NASDAQ TIG...
View ArticlePatients with multiple autoimmune diseases have unique concerns physician needs
BOSTON Rheumatologists need to do more to better understand the unique burdens and frustrations experienced by patients with multiple immunemediated inflammatory diseases according to Lilly Stairs head...
View ArticlePredictImmune secures £4.3m in funding for Crohn's disease biomarker test
PredictImmune has secured £4.3m investment from Wellcome Trust to assess the clinical utility of its prognostic test In Crohns disease.
View Article